ABCLAbCellera Biologics Inc.

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-45.0% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$73M-1440.7% margin

Net Income

-$34M-677.4% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

-22.4%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$24M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$304M

Stockholders' Equity

$1.1B

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$9M	-45.0%
Gross Profit	$5M	$9M	-45.0%
Operating Income	-$73M	-$66M	-10.1%
Net Income	-$34M	-$47M	+27.4%

Revenue Segments

Research Fees

$10M94%

License

$651,0006%

ABCL Q4 2024 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena